Compare KeyCorp (KEY) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Medpace Holdings Inc — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays a 4.08% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Medpace Holdings Inc for 14 Days on average.
| KEY | MEDP | |
|---|---|---|
Market Cap | $21.45B | $16.82B |
Volume | 19,450,846 | 223,093 |
Sector | Financials | Health |
52-Week High | $23.99 | $630.19 |
52-Week Low | $16.78 | $393.42 |
Typical Hold Time | 66 Days | 14 Days |
Enterprise Value | $34.63B | $16.44B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.1, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly EPS beats. Recent news includes a prime rate hike to 7.00% and executive appointments, while the dividend remains frozen.
The outlook is mixed: analyst consensus is bullish with a $25.00 price target, but technical weakness and competitive dividend pressures pose risks. Revenue growth and share buybacks support upside, yet interest rate sensitivity and margin pressures require monitoring for sustained performance.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
